Advertisement

Zusammenfassung

Piracetam gilt als die erste Substanz aus der heute so bezeichneten Gruppe der Antidementiva. Obwohl Piracetam chemisch gesehen ein Abkömmling der Gamma Aminobuttersäure (GABA) ist, gibt es trotz dieser strukturellen Verwandtschaft im Tierversuch keinerlei Effekte auf die Aufnahme, den Gehalt oder die Aktivität von GABA in verschiedenen Hirnregionen. Der pharmakologische Wirkmechanismus von Piracetam wurde im Tierexperiment ausführlich untersucht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aantaa E, Meurman OH (1975) Morphological brain changes induced by alcohol and aging. In: Racagni G, Mendlewiecz J (eds) Treatment of age-related cognitive dysfunction pharmacological and clinical evaluation. Karger, Basel, pp 63–68 (Int Acad Biomed Drug Res, vol 2)Google Scholar
  2. Baltes EL, Gobert JG (1977) Modeies pharmacocinétiques chez le rat, le chien et l’homme (administration orale). UCB-Publ Symp Europ Pharmacocinétique, Bruxelles, pp 99–105Google Scholar
  3. Bartus RT, Dean III RL, Sherman KA, Friedmann E, Beer B (1981) Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 2: 105–111PubMedCrossRefGoogle Scholar
  4. Behring B, Müller WE (1985) The interaction of piracetam with several neurotransmitter receptors in the central nervous system. The relative specifity for H-glutamate sites. Arzneimittelforschung /Drug Res 35: 1350–1352Google Scholar
  5. Benesova O (1985) Interaction of nootropic drugs pyritinol and piracetam with the dopaminergic system. Activ Nerv [Suppl 27] 4: 284–285Google Scholar
  6. Bente D, Glatthaar G, Ulrich G, Lewinsky M (1978) Piracetam und Vigilanz. Elektronenen-cephalographische und klinische Ergebnisse einer Langzeitmedikation bei gerontopsychiatrischen Patienten. Arzneimittelforschung/ Drug Res 28: 9–16Google Scholar
  7. Benzi G, Pastoris O, Villa RR, Giuffrida AM (1985) Influence of aging and exogeneous substances on cerebral energy metabolism in posthypoglycemic recovery. Biochem Pharmacol 34: 1477–1483PubMedCrossRefGoogle Scholar
  8. BGA (1991) Bekanntmachungen der Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsbereich „Demenz“ (Phase III). Bundesgesundhbl 7/91: 342–350Google Scholar
  9. Bjürwill BB (1985) Behandlung des hirnorganischen Psychosyndroms bei Alterspatienten mit Piracetam. Stockholm, Blackebergs Hospital. UCB-Chemie, KölnGoogle Scholar
  10. Bonifaci JF, Ferran C, Laborth H (1982) Action du Piracetam sur certaines etappes du métabolisme du cerveau de rat. Agressologie 23: 127–129Google Scholar
  11. Brandao F, Cadete-Leite A, Paula-Barbosa MM (1992) Morphological brain changes induced by alkohol and aging. In: Racagni G, Mendlewiecz J (eds) Treatment of age-related cognitive dysfunction pharmacological and clinical evaluation. Karger, Basel, pp 63–68 (Int Acad Biomed Drug Res, vol 2)Google Scholar
  12. Bryant RC, Petty F, Byrne WL (1973) Effects of Piracetam (SKF 38462) on acquisition, retention and activity in the goldfish. Psychopharmacologia (Berlin) 29: 121–130CrossRefGoogle Scholar
  13. Buresova O, Bures J (1976) Piracetam-induced facilitation of interhemispheric transfer of visual information in rats. Psychopharmacologia (Berlin) 46: 93–102CrossRefGoogle Scholar
  14. Burnotte RE, Gobert JG, Temmermann JJ (1973) Piracetam (2-pyrrolidinone acetamide) induced modifications of the brain polyribosome pattern in ageing rats. Biochem Pharmacol 22: 811–814PubMedCrossRefGoogle Scholar
  15. Calliauw L, Marchau M (1975) Clinical trial of Piracetam in disorders of consciouness due to head injury. Acta Anesth Belg 2: 51–60Google Scholar
  16. Chase C, Tallal P (1987) Piracetam and dyslexia. A thirty-six week double-blind clinical trial. Child Health Dev 5: 140–147Google Scholar
  17. Connors CK, Reader M, Reiss A, Caldwell J, Caldwell L, Adesman A, Mayer L (1987) The effects of piracetam upon visual event-related potentials in dyslexic children. Psychophysiology 24: 513–521CrossRefGoogle Scholar
  18. Cornely M, Henkel E, Trapp H (1978) Zur Pharmakokinetik von Piracetam während der Geburt. Fortschr Med 96: 1881–1885PubMedGoogle Scholar
  19. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M (1993) Long-term and high-dose piracetam traetment of Alzheimer’s disease. Neurology 43: 301–304PubMedCrossRefGoogle Scholar
  20. De Araujo JT, Nero GS (1977) Piracetam and acetamide in sickle-cell disease. Lancet ii: 411–413Google Scholar
  21. De Deyn PP, Minderhoud JM, Deberdt W, Van Vleymen B (1996) Piracetam in acute stroke study (PASS). J Neurol 243, 6[Suppl 2]: 111Google Scholar
  22. De Deyn PP, De Reuck J, Deberdt W, Vlientinck B, Orgogozo J-M (1997) Treatment of acute ischemic stroke with Piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 28: 2347–2352PubMedCrossRefGoogle Scholar
  23. De Melo GUS (1976) Piracetam in sickle-cell anaemia. Lancet i: 1139–1140CrossRefGoogle Scholar
  24. Dencker SJ, Wilhelmson G, Carlsson E, Bereen FJ (1978) Piracetam and chlormethiazole in acute alcohol withdrawal: a controlled clinical trial. Int Med Res 6: 395–400Google Scholar
  25. Depresseux JC, Salmon E, Cornette M, Franck G (1990) The activity of piracetam in acute stroke patients: final results of a pharmacoclinical study using PET and 15-oxygen. In: Symposium Piracetam: 5 Years Progress in Pharmacology and Clinics, pp 163–166Google Scholar
  26. Di Ianni M, Wilsher CR, Blank MS, Connors CK, Chase CH, Funkenstein HH, Helfgott E, Holmes JM, Lougee L, Maletta GJ, Milewski J, Pirozzolo FJ, Rudel RG, Tallal P (1985) The effects of piracetam in children with dyslexia. Clin Psychopharmacol 5: 272–278CrossRefGoogle Scholar
  27. Dimov S, Nikolov R, Nikolova M (1980) Piracetam effect on the general and local cortical bioelectrical activity depression induced by different agents in cats. EBB9, Annual Meeting, Louvain la NeuveGoogle Scholar
  28. Dimov S, Nikolov R, Nikolova M, Moyandova S (1983) Effect of piracetam in some models of general and local depressions in the cortical bioelectrical activity in cats. Arch Int Pharmacodyn 262: 13–23PubMedGoogle Scholar
  29. Ducarne H, Broekhuysen J, Baltes E, Coupez R, Brouwers L, Polderman J (1980) Pharmacocinetique du piracetam chez l’homme après administration chronique (3 x 3,2 g/j). UCB-Bericht (intern)Google Scholar
  30. Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W (1994) Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin Neuropharmacol 17: 320–331PubMedCrossRefGoogle Scholar
  31. Fischer F, Ehrlich E, Hoffmann H, Hoffmann W (1993) Verkürzung des stationären Aufenthaltes und Einsparung von Tranquilizern beim alkoholbedingten Abstinenzsyndrom und Prädelir. Neuropsychiatrie 7: 147–152Google Scholar
  32. Fleischmann UM (1990) Wirkeffekte nootroper Substanzen bei Alterspatienten — eine Sekundäranalyse am Beispiel von Piracetam. Z Gérant Psychiatr 4: 285–304Google Scholar
  33. Giurgea C (1976) Piracetam: nootropic pharmacology of neurointegrative activity. Curr Dev Psychopharmacol 3: 223–273Google Scholar
  34. Giurgea C, Moyersoons F (1970) Differential pharmacological reactivity of three types of cortical evoked potentiale. Arch Int Pharmacodyn Ther 188: 401–404PubMedGoogle Scholar
  35. Giurgea C, Lefevre D, Lescreniere C, David-Remacle M (1971) Pharmacological protection against hypoxia induced amnesia in rats. Psychopharmacologia (Berlin) 20: 160–168CrossRefGoogle Scholar
  36. Gobert JG (1972) Genèse d’un medicament: le Piracetam. Metabolisation et recherche biochemique J Pharm Belg 27: 281–304Google Scholar
  37. Gobert JG, Baltes EL (1977) Availibility and plasma clearance of piracetam in man. I Farmaco 32:83Google Scholar
  38. Gouliaev AH, Senning A (1994) Full-length review. Piracetam and other structurally related nootropics. Brain Res Rev 19: 180–222Google Scholar
  39. Grotemeyer KH (1997) Piracetam vs Aspirin in secondary stroke prophylaxis. A two year double-blind follow up study. J Neurol 244 [Suppl]: 71CrossRefGoogle Scholar
  40. Grotemeyer KH, Husstedt IW, Schlake HP (1995) Piracetam and ASA in secondary stroke prophylaxis. A two year follow up pilot study. Cereb Blood Flow Metab 15: 129Google Scholar
  41. Grotemeyer KH, Hofferberth B, Hirschberg M (1986) Normalisierung hyperreaktiver Thrombozyten bei Patienten mit TIAs unter Piracetam? Nervenarzt 57: 180–183PubMedGoogle Scholar
  42. Grotemeyer KH, Hussteto IW, Schlake HP (1995) Piracetam and ASA in secondary stroke prophylaxis. A two year follow up study. J Cereb Blood Flow Metab 15: 129Google Scholar
  43. Hakkarainen H, Hakamies L (1978) Piracetam in the treatment of post-concussional syndrome. A double blind study. Eur Neurol 17: 50–55PubMedCrossRefGoogle Scholar
  44. Heiss WD, Ilsen HW, Wagner R, Pawlik G, Wienhard K (1983) Remote functional depressions of glucose metabolism in stroke and its alteration in activating drugs. Positron emission tomography of the brain. Springer, Berlin Heidelberg New York Tokyo, pp 162–168CrossRefGoogle Scholar
  45. Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szelies B, Pawlik B, Herholz K (1988) Effect of piracetam on cerebral glucose metabolism in Alzheimer’s disease as measured by positrom emission tomography. J Cereb Blood Flow Metab 8: 613–617PubMedCrossRefGoogle Scholar
  46. Herrmann WM, Kern I (1987) Nootropika: Wirkung und Wirksamkeit. Eine überlegung am Beispiel einer Phase III-Prüfung mit Piracetam. Nervenarzt 58: 358–364PubMedGoogle Scholar
  47. Herrmann WD, Stephan K (1992) Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatiens with dementia syndroms taking piracetam. Int Psychogeriat 4: 25–43CrossRefGoogle Scholar
  48. Herrschaft H (1978) Die Wirkung von Piracetam auf die Gehirndurchblutung des Menschen. Med Klin 73: 195–202PubMedGoogle Scholar
  49. Herrschaft H (1988) Die Wirksamkeit von Piracetam bei der akuten cerebralen Ischämie des Menschen. Klinisch kontrollierte Doppelblindstudie Piracetam/10% Dextran 40 versus Placebo/10% Dextran 40. Med Klin 83: 667–677Google Scholar
  50. Herrschaft H (1993) Moderne Therapiestrategien beim akuten ischämischen Hirninfarkt. In: Schmidt J (Hrsg) Aspekte der Pharmakotherapie mit Zerebroprotektiva/Nootropika. Barth, Leipzig, S 7–133Google Scholar
  51. Hoffmann W, Rostock A (1983a) Wirkung von Nootropika auf die durch elektrokonvulsiven Schock ausgelöste retrograde Amnesie. Pharmazie 38: 869–871PubMedGoogle Scholar
  52. Hoffmann W, Rostock A (1983b) Der Einfluß von Nootropika auf die durch wiederholte Alkoholgabe beeinträchtigte Lernleistung von Ratten. Zbl Pharm Pharmakother Lab 122: 186Google Scholar
  53. Huber W, Willmes K, Poeck K, Van Vleymen B, Deberdt W (1997) Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch Phys Med Rehabil 78: 245–250PubMedCrossRefGoogle Scholar
  54. Ikeda A, Shibasaki H, Tashiro K, Mizuno Y, Kimura J (1996) Clinical trial of Piracetam in patients with myoclonus: nationwide multiinstitution study in Japan, vol 11, No 6. Mov Disord: 691–700PubMedCrossRefGoogle Scholar
  55. Karacostas D, Artemis N, Giannopoulos S (1995) Cortical myoclonus: a valid human model for the demonstration of the neuromodulatory effects of piracetam. Acta Ther 21: 77–84Google Scholar
  56. Karoutas G, Artemis N, Karakostas D, Logothetis J (1988) A randomizied double-blind placebo controlled study of piracetam in patients with acute ischaemic cerebral infarcts in the carotid territory. Acta Neurochir 91: 100–105CrossRefGoogle Scholar
  57. Koskiniemi M, Van Vleymen B (1996) Piracetam in myoclonus, a double-blind, randomised, cross-over, multicentre study to evaluate the efficacy, tolerance and safety of 3 different dosages of piracetam, controlled by a placebo, in myoclonus. J Neurol 243[Suppl 2]: 62Google Scholar
  58. Krejci I, Schuh J, Valchar M, Benesova O, Sulc J, Kubik V, Pavlik A (1982) The effect of pyritinol and piracetam on the development of behavioural and biochemical deviations induced by short-term neonatal protein synthesis inhibition in rats. Activ Nerv Sup (Praha) 24: 256–259Google Scholar
  59. Kruse H, Kohler H (1978) Memory enhancing effects of piracetam in aged rats. Fed Proc 37: 888Google Scholar
  60. Maillis A, Karayanidis F, Koutsoukos E, Angelo-Poulus E, Stefanis C (1988) Effect of piracetam on single central neurons. Neuropsychobiology 19: 139–145PubMedCrossRefGoogle Scholar
  61. Mezitis NR (1976) Einflüsse von Piracetam auf kortikale und subkortikale Hirngebiete der Katze. Elektrophysiologische Makro-und Mikroableitungen. Dissertation, HeidelbergGoogle Scholar
  62. Michel CM, Lehmann D (1993) Single doses of Piracetam affect 42-channel event-related potential microstate maps in a cognitive paradigm. Neuropsychobiology 28: 212–221PubMedCrossRefGoogle Scholar
  63. Mindus P, Cronholm B, Levander SE, Schalling D (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 54: 150–160PubMedCrossRefGoogle Scholar
  64. Mindus P (1978) Sub-optimal levels of vigilance in elderly patients with respiratory disorders: effects of piracetam. 11th CINP Congress, ViennaGoogle Scholar
  65. Ming A, Winterton R, Fritz VU, Esser R, Hinton SA (1990) Piracetam versus placebo in first acute, non-haemorragic carotid territory stroke. A double-blind study. Int Symp on Progress of Piracetam, Athen. Ciencia y Medicina, Madrid, pp 88–93Google Scholar
  66. Moriau M, Crasborn L, Lavenne-Pardonge E, Frenckell R, Col-Debeys Ch (1993) Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung/Drug Res 43,2: 110–118Google Scholar
  67. Müller WE (1988) Veränderung zentraler Neurorezeptoren unter besonderer Berücksichtigung der m-Cholinrezeptoren, ein Aspekt des biologischen Alterns. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 42–61CrossRefGoogle Scholar
  68. Müller WE, Koch S (1997) Effects of Piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 53: 135–140PubMedCrossRefGoogle Scholar
  69. Müller WE, Hartmann H, Koch S, Scheuer K, Stoll S (1994) Neurotransmission in agingtherapeutic aspects In: Racagni G, Brunelleo N, Langer SZ (eds) Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Karger, Basel, pp 166–173 (Int Acad Biomed Drug Res 7)Google Scholar
  70. Nickolson VJ, Wolthuis OL (1976) Protein metabolism in the rat cerebral cortex in vivo and in vitro as affected by the aquisition-enhancing drug piracetam. Biochem Pharmacol 25: 2241–2244PubMedCrossRefGoogle Scholar
  71. Nikolova M, Tsikalova R, Nikolov R, Taskov M (1979) Simultaneous investigation of the cerebral circulation and cortical bioelectrical activity in dogs under the influence of piracetam. Meth Find Exp Clin Pharmacol 2: 97–104Google Scholar
  72. Nybäck H, Wiesel FA, Skett P (1979) Effects of piracetam on brain monoamine metabolism and serum prolactin levels in rat. Psychopharmacology 61: 235–238PubMedCrossRefGoogle Scholar
  73. Olpe H-R, Steinmann MW (1982) The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons. J Neural Transm 55: 101–109PubMedCrossRefGoogle Scholar
  74. Ostrowskaya RU, Hoffmann W, Molodwakin GM (1983) Untersuchungen zur antihypoxischen Wirksamkeit von Tisochromid (16-244) im Vergleich zu Piracetam. Pharmazie 38: 251–253Google Scholar
  75. Ostrowski J, Keil M (1978) Autoradiographische Untersuchungen zur Verteilung von 14-C-Piracetam im Affengehirn. Arzneimittelforschung/ Drug Res 28: 29–35Google Scholar
  76. Ostrowski J, Keil M, Schraven E (1975) Autoradiographische Untersuchungen zur Verteilung von Piracetam-14 C bei Ratte und Hund. Arzneimittelforschung/Drug Res 25: 589–596Google Scholar
  77. Ott E (1988) Behandlungsergebnisse mit Piracetam bei der Multi-lnfarkt-Demenz. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 162–168CrossRefGoogle Scholar
  78. Pede JP, Schimpfessel L, Crokaert T (1971) The action of piracetam on the oxidative phosphorylation. Arch Int Physiol Biochim 79: 1036–1037Google Scholar
  79. Pede JP, Schimpfessel L, Crokaert R (1983) The action of piracetam on the oxidative phosphorylation. Drugs Exp Clin Res 9: 853–871Google Scholar
  80. Pellegata R (1981) Cyclic GABA-GABOB analogues. III. Synthesis and biochemical activity of new alkyl and acyl derivatives of 4-hydroxy-2-pyrrolidinone. June Farmaco (Edizione Scientifical) 36(10): 845–855Google Scholar
  81. Perez GM (1981) Evaluation of the clinical efficacy of piracetam in the deterioration of the intellectual functions of a geriatric population: a double-blind study. Second International Symposium on Nootropic Drugs, Mexico. UCB-Publ, pp 53–62Google Scholar
  82. Peuvot J, Schanck A, Deleers M, Brasseurs R (1995) Piracetam-induced changes to membrane physical properties. Biochem Pharmacol 50,8: 1129–1134 (UCB 1993 Pharmacotoxicological expert report AELE93 B1615/4)PubMedCrossRefGoogle Scholar
  83. Platt D, Hering H, Hering FJ (1974) Messungen Iysosomaler Enzym-Aktivitäten sowie von Leuzin-lnkorporationsraten im Gehirn junger und alter Ratten nach Gabe von Piracetam. Arzneimittelforschung/Drug Res 24: 1588–1590Google Scholar
  84. Platt D, Horn J, Summa JO, Schmitt-Ruth R, Reinlein B, Kaunitz J, Krönert E (1992) Zur Wirksamkeit, von Piracetam bei geriatrischen Patienten mit akuter cerebraler Ischämie. Med Welt 43: 181–190Google Scholar
  85. Raego LK, Allkimets LH, Zarkovsky AM (1981) Effects of Piracetam on the central dopaminergic transmission. Naunyn Schmiedebergs Arch Pharmacol 319: 17–36Google Scholar
  86. Reuse-Blom S, Polderman J (1980) Influence of Piracetam upon the pial micro-circulation. Gefäß-Patient-Therapie, pp 62–64 (6. Int Angiol und Angiograph Sem, Baden-Baden)Google Scholar
  87. Richardson AE, Bereen FJ (1977) Effects of Piracetam on level consciousness after neurosurgery. Lancet ii: 1110–1111CrossRefGoogle Scholar
  88. Saletu B, Hitzenberger G, Grünberger J, Anderer P, Zyhlarz G, Linzmayer L, Rameis H (1995) Double-blind, placebo-controlled, pharmakokinetic and-dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J Clin Pharm Ther 33: 249–262Google Scholar
  89. Sara SJ, Lefevre D (1972) Hypoxia-induced amnesia in one-trial learning and pharmacological protection by piracetam. Psychopharmacologia (Berlin) 25: 32–40CrossRefGoogle Scholar
  90. Sara SJ, David-Remacle M (1974) Recovery from electroconvulsive shock-induced amnesia by exposure to the training environment: pharmacological enhancement by piracetam. Psychopharmacologia (Berlin) 36: 59–66CrossRefGoogle Scholar
  91. Schenk GK, Engelmeier M-P, Lodemann E, Pach J (1982) Vigilanz, hirnorganisches Psychosyndrom und Pharmakotherapie. Aspekte der Reversibilität. In: Bente D, Coper H, Kanowski S (Hrsg) Hirnorganische Psychosyndrome im Alter — Konzepte und Modelle für die pharmakotherapeutische Forschung. Springer, Berlin Heidelberg New York Tokyo, S 74–113CrossRefGoogle Scholar
  92. Schindler U, Rush DK, Fielding S (1984) Nootropic drugs: animal models for studying effects on cognition. Drug Dev Res 4: 567–576CrossRefGoogle Scholar
  93. Schulz HU, Wittler T (1980) Age-related changes in pharmacokinetics of piracetam in man. Arch Pharmacol [Supp]: 38–46Google Scholar
  94. Skondia V, Kabes J (1985) Piracetam in alcoholic psychosis. A double-blind cross-over, placebo controlled study. Int Med Res 13: 185–187Google Scholar
  95. Snel H, Lehman E, Vilikonja M (1983) Piracetam in der Behandlung des alkoholbedingten Delirs. Münch Med Wochenschr 42: 947–949Google Scholar
  96. Sonnet J, Gini EK, Cornu G (1985) Essai de prévantion des crisis vaso-occulsives de la drepanocytes homozygote per le piracetam. Ann Soc Belg Med Trop 65: 77–84PubMedGoogle Scholar
  97. Stockmans F, Arnout J, Deckmyn H, Vermylen J (1991) Piracetam has an antiplatelet effect in vivo and in vitro. Thromb Haemost 1744; XIIIth Congress of the International Society on Thrombosis and HaemostasisGoogle Scholar
  98. Stockmans F, Deberdt W, Nyström Å, Nyström E, Stassen JM, Vermylen J, Deckmyn H (1998) Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb Haemost 79: 222–227PubMedGoogle Scholar
  99. Vernon MW, Sorkin EM (1991) Piracetam an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorder. Drugs Aging 1: 17–35PubMedCrossRefGoogle Scholar
  100. Van Vleymen B, Van Zandjicke M (1996) Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg 96: 270–280PubMedGoogle Scholar
  101. Van Vleymen B, De Reuck (1998) The safety of high dose piracetam in the treatment of acute stroke. Abstract, 4th International Conference on Stroke and 1st Conference of the Mediterranean Stroke Society, Marrakesch, March 4–7, 1998. Eur J Neurol 5 [Suppl]Google Scholar
  102. Van Vleymen B, Marien P, Saerens J, De Deyn PD (1998) Piracetam in the treatment of aphasia in acute stroke. Abstract, 4th International Conference on Stroke and 1st Conference of the Mediterranean Stroke Society, Marrakesch, March 4–7, 1998. Eur J Neurol 5 [Suppl]Google Scholar
  103. Welbel L (1981) Piracetam v/s Pyritinol in the treatment of psychoorganic syndrome patients. Second International Symposium of Nootropic Drugs, Mexico. UCB-Publ, pp 66–70Google Scholar
  104. Weth G (1983) The influence of piracetam on the cyclic adenosine monophosphate (cAMP) concentration in the brain and colon of guinea pigs. Arzneimittelforschung/Drug Res 3 (I) 6: 812–814Google Scholar
  105. Wilsher CR, Taylor EA (1994) Piracetam in developmental reading disorders: a review. Eur Child Adolesc Psychiatry 3: 59–71CrossRefGoogle Scholar
  106. Woelk H (1979) Effects of piracetam on the incorporation of 32 P into the phospholipids of neu rons and glial cells isolated from rabbit cerebral cortex. Pharmakopsychiatr 12: 251–256CrossRefGoogle Scholar
  107. Woelk H, Peiler-Ichikawa K (1978) The action of piracetam on the formation of ethanolamineplasmalogen by neuronal microsomes of the developing brain. UCB-Bericht (intern)Google Scholar
  108. Wolthuis OL (1971) Experiments with UCB 6215, a drug which enhances acquisition in rats: its effects compared with those of metamphetamine. Eur J Pharmacol 16: 283–297PubMedCrossRefGoogle Scholar
  109. Wurtmann RJ, Magil DC, Reinstein DK (1981) Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci 28: 1091–1093CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • S. Kanowski

There are no affiliations available

Personalised recommendations